SCHEMBL335952

SCHEMBL335952

CC(C)(C)ON(C=O)C1CCNCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6221301 0.89 SLC6A4 (0.33)
SCHEMBL1851488 0.89 SLC6A4 (0.33)
SCHEMBL2447410 0.89 SLC6A4 (0.33)
SCHEMBL28177299 0.80 ADH1A (0.32)
SCHEMBL29024656 0.80 ADH1A (0.32)
SCHEMBL28178187 0.80 ADH1A (0.32)
SCHEMBL3316113 0.78 HSD11B1 (0.31)
SCHEMBL3852707 0.78
SCHEMBL385268 0.78
SCHEMBL5665104 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11987560-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2024-05-21 US disclosed
EP-3496721-B1 TREATMENT OF MERKEL CELLL CARCINOMA CELGENE QUANTICEL RES INC (US) 2023-12-06 EP disclosed
EP-4286381-A2 TREATMENT OF MERKEL CELLL CARCINOMA Celgene Quanticel Research, Inc. (US) 2023-12-06 EP disclosed
US-20220153706-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2022-05-19 US disclosed
EP-3137169-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2021-11-10 EP disclosed
US-11084793-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2021-08-10 US disclosed
US-11028066-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2021-06-08 US disclosed
US-10960005-B2 Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas CELGENE QUANTICEL RESEARCH, INC. (US) 2021-03-30 US disclosed
EP-3371152-B1 COMPOSITIONS COMPRISING AN INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 HAVING A PYRIMIDINE RING AND ITS USE IN THE TREATMENT OF CANCER CELGENE QUANTICEL RES INC (US) 2020-12-23 EP disclosed
US-10849898-B2 Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas CELGENE QUANTICEL RESEARCH, INC. (US) 2020-12-01 US disclosed
US-20060084688-A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor BARTA THOMAS E 2006-04-20 US disclosed
US-6890937-B2 Aromatic sulfone hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION (US) 2005-05-10 US disclosed
WO-2005040159-A1 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2005-05-06 WO disclosed
US-6750233-B2 SELECTIVITY PHARMACIA CORPORATION 2004-06-15 US disclosed
US-20040048852-A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-03-11 US disclosed
US-6541489-B1 Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1 G. D. SEARLE & COMPANY 2003-04-01 US disclosed
US-20020177588-A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2002-11-28 US disclosed
EP-1229025-A1 NOVEL QUINAZOLINE DERIVATIVES Japan Energy Corporation (JP) 2002-08-07 EP disclosed
US-20010039287-A1 AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR PHARMACIA CORPORATION 2001-11-08 US disclosed
US-20010014688-A1 AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR BARTA THOMAS E (US) 2001-08-16 US disclosed